*Some Market data delayed by 15 mins.

NeuroBo Pharmaceuticals, Inc. Common Stock

Symbol: NRBO (NASDAQ)
0.00 ▼ (-100.00%) -3.020

Company Description:
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Key Stats
  • Today's Open: $0
  • Today's High: $0
  • Today's Low: $0
  • Today's Volume: 0
  • Yesterday Close: $3.02
  • Yesterday High: $3.19
  • Yesterday Low: $2.99
  • Yesterday Volume: 42.19K
  • Last Min Volume: 0
  • Last Min High: $0
  • Last Min Low: $0
  • Last Min VWAP: $0
Company Profile
  • Name: NeuroBo Pharmaceuticals, Inc. Common Stock
  • Website: https://www.neurobopharma.com
  • Listed Date: 2016-08-04
  • Location: CAMBRIDGE, MA
  • Market Status: Active
  • CIK Number: 0001638287
  • SIC Code: 2834
  • SIC description: PHARMACEUTICAL PREPARATIONS
  • Market Cap: $14.82M
  • Round Lot: 100
  • Outstanding Shares: 4.91M
  • Asset Type: CS
RECENT FILINGS FOR NRBO
Filing DateFiling TypeFormat
2024-04-23EFFECTView
2024-04-178-KView
2024-04-168-KView
2024-04-12S-3View
2024-04-018-KView
2024-03-2810-KView
2024-03-288-KView
2024-03-138-KView
2024-03-044View
2024-03-048-KView
2024-02-298-KView
2024-02-148-KView
2024-02-018-KView
2024-01-188-KView
2024-01-098-KView
2023-12-288-KView
2023-12-198-KView
2023-12-078-KView
2023-12-044View
2023-11-1310-QView
Latest News

 

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money. Copyright© 2024, 247MarketNews inc.